1
Bosanac Todd, Ginn John David, Hickey Eugene Richard, Kirrane Thomas Martin, Liu Weimin, Prokopowicz Anthony S, Shih Cheng Kon, Snow Roger John, Turner Michael Robert, Wu Frank, Young Erick Richard, Schlyer Sabine K: Rho kinase inhibitors. Boehringer Ingelheim International, Boehringer Ingelheim Pharma & Co Kg, Bosanac Todd, Ginn John David, Hickey Eugene Richard, Kirrane Thomas Martin, Liu Weimin, Prokopowicz Anthony S, Shih Cheng Kon, Snow Roger John, Turner Michael Robert, Wu Frank, Young Erick Richard, Schlyer Sabine K, MORRIS Michael P, March 27, 2008: WO/2008/036540 (21 worldwide citation)

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compos ...


2
Cywin Charles, Pullen Steven S, Roth Gregory Paul, Snow Roger John, Fleck Roman Wolfgang, Takahashi Hidenori, Winters Michael, Qiao Lei, Nemoto Peter Allen, Moriarity Kevin J, Wang Ji, Bentzien Joerg, Cook Brian, Lo Ho Yin: Substituted benzimidazole compounds. Boehringer Ingelheim Pharmaceuticals, RAYMOND Robert P, February 19, 2004: WO/2004/014905 (8 worldwide citation)

Disclosed are substituted benzimidazole compounds of formula (I) wherein R¿1?, R¿2?, R¿3?, R¿4? and X¿a? are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders an ...


3

4
Dahmann George, Hickey Eugene Richard, Li Xiang, Mao Wang, Marshall Daniel Richard, Morwick Tina Marie, Sibley Robert, Snow Roger John, Sorcek Ronald John, Wu Frank, Young Erick Richard Roush: Rho kinase inhibitors. Boehringer Ingelheim International, Boehringer Ingelheim Pharma & Co Kg, Dahmann George, Hickey Eugene Richard, Li Xiang, Mao Wang, Marshall Daniel Richard, Morwick Tina Marie, Sibley Robert, Snow Roger John, Sorcek Ronald John, Wu Frank, Young Erick Richard Roush, MORRIS Michael P, July 17, 2008: WO/2008/086047 (2 worldwide citation)

Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma.


5
Showell Graham Andrew, Snow Roger John: Process for resolving 1-azabicyclo not 2.2.1 heptane-3-carboxylates. Merck Sharp & Dohme, November 22, 1990: EP0398617-A2 (1 worldwide citation)

A process for preparing a substantially pure enantiomer of a 1-azabicyclo[2.2.1]heptane, 1-azabicyclo[3.2.1] octane or quinuclidine, substituted on the carbon atom beta to the ring nitrogen by a carboxy group, by synthesising and separating diastereomeric derivatives thereof wherein the hydroxy grou ...


6
Snow Roger John, Gao Donghong A, Goldberg Daniel R, Hammach Abdelhakim, Kuzmich Daniel, Morwick Tina Marie, Moss Neil, Prokopowicz Iii Anthony S, Selliah Robert D, Takahashi Hidenori: Heterocyclic compounds useful as inhibitors of tyrosine kinases. Boehringer Ingelheim Pharmaceuticals, RAYMOND Robert P, February 21, 2002: WO/2002/014319 (1 worldwide citation)

Disclosed are novel compounds of formula (I) (see formula I as described in specification) wherein Ar¿1?, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferatio ...


7

8
KIRRANE JR Thomas Martin, MARSHALL Daniel Richard, SIBLEY Robert, SNOW Roger John, SOLEYMANZADEH Fariba, SORCEK Ronald John: INHIBITEURS DES RHO-KINASES, RHO KINASE INHIBITORS. BOEHRINGER INGELHEIM INTERNATIONAL, KIRRANE JR Thomas Martin, MARSHALL Daniel Richard, SIBLEY Robert, SNOW Roger John, SOLEYMANZADEH Fariba, SORCEK Ronald John, MORRIS Michael P, April 26, 2012: WO/2012/054367 (1 worldwide citation)

The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various di ...


9
BOSANAC TODD, GINN JOHN DAVID, HICKEY EUGENE RICHARD, KIRRANE THOMAS MARTIN JR, LIU WEIMIN, PROKOPOWICZ ANTHONY S, SCHLYER SABINE K, SHIH CHENG KON, SNOW ROGER JOHN, TURNER MICHAEL ROBERT, WU FRANK, YOUNG ERICK RICHARD: Inhibiteurs de la RHO-kinase, RHO-Kinase-Hemmer, RHO kinase inhibitors. AERIE PHARMACEUTICALS, November 28, 2012: EP2526948-A1

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-isoquinolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compo ...


10
Snow Roger John, Gao Donghong A, Goldberg Daniel R, Hammach Abdelhakim, Kuzmich Daniel, Morwick Tina Marie, Moss Neil, Prokopowicz Iii Anthony S, Selliah Robert D, Takahashi Hidenori: Composes heterocycliques utiles en tant quinhibiteurs de tyrosine kinases, Heterocyclic compounds useful as inhibitors of tyrosine kinases. Boehringer Ingelheim Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, FETHERSTONHAUGH & CO, February 21, 2002: CA2417635

Disclosed are novel compounds of formula (I) (see formula I as described in specification) wherein Ar1, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, ...